Compare Becton Dickinson and Co (BDX) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Prudential PLC — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $49.41B), while Prudential PLC trades at $27.46 (market cap $34.02B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| BDX | PUK | |
|---|---|---|
Market Cap | $49.41B | $34.02B |
Sector | Health | Financials |
52-Week High | $185.39 | $33.61 |
52-Week Low | $138.62 | $24.98 |
Enterprise Value | $65.51B | $35.46B |
Dividend Yield | 2.32% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $183.71, up 2.27% today, near its consensus price target of $183.00. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $21.84 billion in 2025, with consistent earnings beats in recent quarters, including Q3 2026 EPS of $3.23 beating estimates. The company maintains a dividend of $1.05 per share and recently raised full-year guidance, reflecting operational strength amid tariff pressures.
Outlook remains positive with raised profit guidance and segment growth, but risks include margin pressure from tariffs and a product recall. Analyst sentiment is mixed with 47% buy ratings, suggesting cautious optimism. The stock offers stability as a Dividend Aristocrat with growth catalysts from medical technology advancements, though investors should monitor margin trends and competitive dynamics.
Prudential PLC (PUK) trades at $27.495, down 2.57% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and robust cash flow from operations of $3.61B in 2024. Recent earnings beat expectations in Q4 2025, though Q4 2024 missed. The stock faces headwinds from China regulatory news impacting Asian operations, but analyst consensus remains 50% buy.
The outlook is mixed: attractive valuation and profitability support upside, but regulatory risks in China and bearish technicals pose near-term challenges. Investors should weigh strong cash generation and earnings beats against geopolitical exposures and market sentiment pressures for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
